June 4, 2008
Urodynamix Launches Tetra-NIRS Marketing Trials
VANCOUVER, British Columbia, June 4, 2008 - Urodynamix Technologies Ltd. (TSX-V:URO) today announced that it has initiated marketing trials in the United States to support the launch of the Tetra™ Bladder Monitor System by Laborie Medical Technologies.
The first study is underway at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York. Principal Investigator Dr. Alexis E. Te, MD is Director of the Brady Prostate Center and Co-Director of Urodynamics at NewYork-Presbyterian/Weill Cornell and Associate Professor of Urology at Weill Cornell Medical College.
The primary objective of the study is to evaluate the effectiveness of Tetra for the non-invasive diagnosis of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) in adult patients. Dr. Te is expected to enroll 50 male and female patients in the study to compare the diagnostic sensitivity and selectivity of the Tetra system to that of conventional catheter-based urodynamics procedures.
Laborie received FDA approval for the Tetra system in March 2008 and launched Tetra at the American Urological Association (AUA) Annual Meeting and Exhibition in May 2008. Tetra uses non-invasive near infrared spectroscopy (NIRS) in combination with uroflowmetry and bladder ultrasound to assess bladder function and aid in the diagnosis of LUTS.
Laborie intends to seek Health Canada licensing and CE Mark approval for the Tetra Bladder Monitor System during the second quarter of 2008.
NewYork-Presbyterian Hospital/Weill Cornell Medical Center
NewYork-Presbyterian Hospital/Weill Cornell Medical Center, located in New York City, is one of the leading academic medical centers in the world, comprising the teaching hospital NewYork-Presbyterian and Weill Cornell Medical College, the medical school of Cornell University. NewYork-Presbyterian/Weill Cornell provides state-of-the-art inpatient, ambulatory and preventive care in all areas of medicine, and is committed to excellence in patient care, education, research and community service. Weill Cornell physician-scientists have been responsible for many medical advances – from the development of the Pap test for cervical cancer to the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial for gene therapy for Parkinson’s disease, the first indication of bone marrow’s critical role in tumor growth, and, most recently, the world’s first successful use of deep brain stimulation to treat a minimally-conscious brain-injured patient. NewYork-Presbyterian, which is ranked sixth on the U.S. News & World Report list of top hospitals, also comprises NewYork-Presbyterian Hospital/Columbia University Medical Center, Morgan Stanley Children’s Hospital of NewYork-Presbyterian, NewYork-Presbyterian Hospital/Westchester Division and NewYork-Presbyterian Hospital/The Allen Pavilion. Weill Cornell Medical College is the first U.S. medical college to offer a medical degree overseas and maintains a strong global presence in Austria, Brazil, Haiti, Tanzania, Turkey and Qatar. For more information, visit www.nyp.org and www.med.cornell.edu.
About Laborie Medical Technologies
Founded in 1967 by Ray Laborie, Laborie Medical Technologies is the leading global manufacturer of urodynamics equipment used in the diagnosis and treatment of incontinence, BPH, and voiding dysfunction.
As Laborie enters its 41st anniversary in business, it has established itself as ‘the’ supplier of pelvic floor assessment systems in many key academic centers. Laborie’s AQUARIUS Wireless Urodynamic System is considered the benchmark diagnostic device for clinical trials and medical research. Laborie’s product line includes urodynamic diagnostics, biofeedback/stimulation systems, compact ultrasound, computerized and physical bladder modeling tools, EMR solutions, consumables, as well as accredited education.
The network of installed users has afforded Laborie the opportunity to feed this network with new and exciting technology on a continuous basis. Recently, Laborie introduced the world's most compact, high resolution USB ultrasound system (NuWav™), and it intends on providing Tetra™ technology in the same manner. Laborie has offices in Canada, USA, Belgium, China, UK and now Paris, France and San Paulo, Brazil. It has direct sales and distribution networks in 52 countries across North America, Europe, Asia and Oceania.
About Urodynamix Technologies Ltd.
Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix’s breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.
Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
For more information, please contact:
Craig Pamplin, PhD, CFA
Director, Corporate Development and Communications
Urodynamix Technologies Ltd.
Tel: (604) 638-0247
Email: cpamplin@urodynamix.com
www.urodynamix.com |
